Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats

Autores
Castaño Zubieta, Mirta Raquel; Rossetti, Carlos Alberto; Garcia-Gonzalez, Daniel G.; Maurizio, Estefanía; Hensel, Martha E.; Rice-Ficht, Allison C.; Ficht, Thomas A.; Arenas-Gamboa, Angela M.
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Small ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16MΔvjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x109 CFU of B. melitensis 16MΔvjbR delivered in alginate microcapsules or non-encapsulated. Controls received empty capsules or the commercially available Rev.1 vaccine. Seven months post-vaccination, when animals were sexually mature, all goats were naturally bred using brucellosis-free males, and allowed to carry pregnancies to term. Blood samples to assess the humoral immune response were collected throughout the study. At two months post-delivery, all dams and their offspring were euthanized and a necropsy was performed to collect samples for bacteriology and histology. Interestingly, none of the animals that received the vaccine candidate regardless of the formulation exhibited any clinical signs associated with vaccination nor shed the vaccine strain through saliva, vagina or the milk. Gross and histopathologic changes in all nannies and offspring were unremarkable with no evidence of tissue colonization or vertical transmission to fetuses. Altogether, these data demonstrate that vaccination with the mutant strain 16MΔvjbR is safe for use in the non-pregnant primary host.
Instituto de Patobiología
Fil: Castaño Zubieta, Mirta Raquel. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Rossetti, Carlos Alberto. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Garcia-Gonzalez, Daniel G. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Maurizio, Estefania. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Maurizio, Estefania. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Hensel, Martha E. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Rice-Ficht, Allison C. Texas A&M University. College of Medicine. Department of Molecular and Cellular Medicine; Estados Unidos
Fil: Ficht, Thomas A. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Arenas-Gamboa, Angela M. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fuente
Vaccine 39 (3) : 617-625 (Enero 2021)
Materia
Brucella melitensis
Brucelosis
Vacuna
Microencapsulación
Goats
Brucellosis
Vaccines
Microencapsulation
Caprinos
Nivel de accesibilidad
acceso restringido
Condiciones de uso
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/9111
Acceder
id INTADig_fa7a36a470b2328ccd43df9fbc73412b
oai_identifier_str oai:localhost:20.500.12123/9111
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goatsCastaño Zubieta, Mirta RaquelRossetti, Carlos AlbertoGarcia-Gonzalez, Daniel G.Maurizio, EstefaníaHensel, Martha E.Rice-Ficht, Allison C.Ficht, Thomas A.Arenas-Gamboa, Angela M.Brucella melitensisBrucelosisVacunaMicroencapsulaciónGoatsBrucellosisVaccinesMicroencapsulationCaprinosSmall ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16MΔvjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x109 CFU of B. melitensis 16MΔvjbR delivered in alginate microcapsules or non-encapsulated. Controls received empty capsules or the commercially available Rev.1 vaccine. Seven months post-vaccination, when animals were sexually mature, all goats were naturally bred using brucellosis-free males, and allowed to carry pregnancies to term. Blood samples to assess the humoral immune response were collected throughout the study. At two months post-delivery, all dams and their offspring were euthanized and a necropsy was performed to collect samples for bacteriology and histology. Interestingly, none of the animals that received the vaccine candidate regardless of the formulation exhibited any clinical signs associated with vaccination nor shed the vaccine strain through saliva, vagina or the milk. Gross and histopathologic changes in all nannies and offspring were unremarkable with no evidence of tissue colonization or vertical transmission to fetuses. Altogether, these data demonstrate that vaccination with the mutant strain 16MΔvjbR is safe for use in the non-pregnant primary host.Instituto de PatobiologíaFil: Castaño Zubieta, Mirta Raquel. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; ArgentinaFil: Rossetti, Carlos Alberto. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; ArgentinaFil: Garcia-Gonzalez, Daniel G. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados UnidosFil: Maurizio, Estefania. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; ArgentinaFil: Maurizio, Estefania. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Hensel, Martha E. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados UnidosFil: Rice-Ficht, Allison C. Texas A&M University. College of Medicine. Department of Molecular and Cellular Medicine; Estados UnidosFil: Ficht, Thomas A. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados UnidosFil: Arenas-Gamboa, Angela M. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados UnidosElsevier2021-04-16T14:43:46Z2021-04-16T14:43:46Z2021-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/9111https://www.sciencedirect.com/science/article/pii/S0264410X203147300264-410Xhttps://doi.org/10.1016/j.vaccine.2020.11.033Vaccine 39 (3) : 617-625 (Enero 2021)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repograntAgreement/INTA/PNSA-1115052/AR./Epidemiología y desarrollo de estrategias para la prevención y control de enfermedades que afectan la salud pública, enfermedades exóticas y limitantes del comercio internacional.info:eu-repo/semantics/restrictedAccess2025-10-16T09:30:03Zoai:localhost:20.500.12123/9111instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:30:04.052INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
title Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
spellingShingle Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
Castaño Zubieta, Mirta Raquel
Brucella melitensis
Brucelosis
Vacuna
Microencapsulación
Goats
Brucellosis
Vaccines
Microencapsulation
Caprinos
title_short Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
title_full Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
title_fullStr Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
title_full_unstemmed Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
title_sort Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MDvjbR strain in goats
dc.creator.none.fl_str_mv Castaño Zubieta, Mirta Raquel
Rossetti, Carlos Alberto
Garcia-Gonzalez, Daniel G.
Maurizio, Estefanía
Hensel, Martha E.
Rice-Ficht, Allison C.
Ficht, Thomas A.
Arenas-Gamboa, Angela M.
author Castaño Zubieta, Mirta Raquel
author_facet Castaño Zubieta, Mirta Raquel
Rossetti, Carlos Alberto
Garcia-Gonzalez, Daniel G.
Maurizio, Estefanía
Hensel, Martha E.
Rice-Ficht, Allison C.
Ficht, Thomas A.
Arenas-Gamboa, Angela M.
author_role author
author2 Rossetti, Carlos Alberto
Garcia-Gonzalez, Daniel G.
Maurizio, Estefanía
Hensel, Martha E.
Rice-Ficht, Allison C.
Ficht, Thomas A.
Arenas-Gamboa, Angela M.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Brucella melitensis
Brucelosis
Vacuna
Microencapsulación
Goats
Brucellosis
Vaccines
Microencapsulation
Caprinos
topic Brucella melitensis
Brucelosis
Vacuna
Microencapsulación
Goats
Brucellosis
Vaccines
Microencapsulation
Caprinos
dc.description.none.fl_txt_mv Small ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16MΔvjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x109 CFU of B. melitensis 16MΔvjbR delivered in alginate microcapsules or non-encapsulated. Controls received empty capsules or the commercially available Rev.1 vaccine. Seven months post-vaccination, when animals were sexually mature, all goats were naturally bred using brucellosis-free males, and allowed to carry pregnancies to term. Blood samples to assess the humoral immune response were collected throughout the study. At two months post-delivery, all dams and their offspring were euthanized and a necropsy was performed to collect samples for bacteriology and histology. Interestingly, none of the animals that received the vaccine candidate regardless of the formulation exhibited any clinical signs associated with vaccination nor shed the vaccine strain through saliva, vagina or the milk. Gross and histopathologic changes in all nannies and offspring were unremarkable with no evidence of tissue colonization or vertical transmission to fetuses. Altogether, these data demonstrate that vaccination with the mutant strain 16MΔvjbR is safe for use in the non-pregnant primary host.
Instituto de Patobiología
Fil: Castaño Zubieta, Mirta Raquel. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Rossetti, Carlos Alberto. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Garcia-Gonzalez, Daniel G. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Maurizio, Estefania. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patobiología; Argentina
Fil: Maurizio, Estefania. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Hensel, Martha E. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Rice-Ficht, Allison C. Texas A&M University. College of Medicine. Department of Molecular and Cellular Medicine; Estados Unidos
Fil: Ficht, Thomas A. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
Fil: Arenas-Gamboa, Angela M. Texas A&M University. College of Veterinary Medicine & Biomedical Sciences. Department of Veterinary Pathobiology; Estados Unidos
description Small ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16MΔvjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x109 CFU of B. melitensis 16MΔvjbR delivered in alginate microcapsules or non-encapsulated. Controls received empty capsules or the commercially available Rev.1 vaccine. Seven months post-vaccination, when animals were sexually mature, all goats were naturally bred using brucellosis-free males, and allowed to carry pregnancies to term. Blood samples to assess the humoral immune response were collected throughout the study. At two months post-delivery, all dams and their offspring were euthanized and a necropsy was performed to collect samples for bacteriology and histology. Interestingly, none of the animals that received the vaccine candidate regardless of the formulation exhibited any clinical signs associated with vaccination nor shed the vaccine strain through saliva, vagina or the milk. Gross and histopathologic changes in all nannies and offspring were unremarkable with no evidence of tissue colonization or vertical transmission to fetuses. Altogether, these data demonstrate that vaccination with the mutant strain 16MΔvjbR is safe for use in the non-pregnant primary host.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-16T14:43:46Z
2021-04-16T14:43:46Z
2021-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/9111
https://www.sciencedirect.com/science/article/pii/S0264410X20314730
0264-410X
https://doi.org/10.1016/j.vaccine.2020.11.033
url http://hdl.handle.net/20.500.12123/9111
https://www.sciencedirect.com/science/article/pii/S0264410X20314730
https://doi.org/10.1016/j.vaccine.2020.11.033
identifier_str_mv 0264-410X
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repograntAgreement/INTA/PNSA-1115052/AR./Epidemiología y desarrollo de estrategias para la prevención y control de enfermedades que afectan la salud pública, enfermedades exóticas y limitantes del comercio internacional.
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Vaccine 39 (3) : 617-625 (Enero 2021)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1846143533899055104
score 12.712165

Publicaciones similares